Expand BDRX Menu
BDRX MENU

BDRX Latest Press Releases

-- December 1, 2025 --

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Globe Newswire 8:30 AM

-- November 24, 2025 --

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Globe Newswire 8:30 AM

-- November 3, 2025 --

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion Globe Newswire 8:30 AM

-- October 6, 2025 --

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA - IGC Conference on October 11, 2025 Globe Newswire 8:30 AM

-- September 12, 2025 --

Interim results for the six months ended June 30, 2025 Globe Newswire 8:30 AM

-- September 8, 2025 --

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled ACCESS Newswire 7:00 AM

-- August 18, 2025 --

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Globe Newswire 8:30 AM

-- July 31, 2025 --

ADR Ratio Change Effective Globe Newswire 9:30 AM

-- July 28, 2025 --

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market ACCESS Newswire 7:00 AM

-- July 15, 2025 --

ADR Ratio Change Globe Newswire 4:30 PM

-- July 14, 2025 --

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes